CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BCAL Diagnostics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BCAL Diagnostics Ltd
Suite 506, Level 5, 50 Clarence Street
SYDNEY, NSW  2000  Australia Ticker: BDXBDX
Business Summary
BCAL Diagnostics Limited is an Australia-based biotechnology company dedicated to advancing early and accurate breast cancer detection. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. Its non-invasive blood test, BREASTEST plus, is the product in the Company’s BREASTEST range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST plus is a class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST plus is a rule-out test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20246/30/2024Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3826 Laboratory analytical instruments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board JayneShaw 2/15/2010 2/15/2010
Chief Executive Officer ShaneRyan 4/2/2024 9/21/2023
Chief Financial Officer, Company Secretary Guy A.Robertson 3/16/2021 3/16/2021
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 365,967,890 (As of 12/31/2024)
Shareholders: 771
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, June 8, 2025